Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 57.36 CNY -3.3% Market Closed
Market Cap: 42.6B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hangzhou Tigermed Consulting Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Receivables
ÂĄ4.3B
CAGR 3-Years
31%
CAGR 5-Years
31%
CAGR 10-Years
33%
WuXi AppTec Co Ltd
SSE:603259
Total Receivables
ÂĄ10.1B
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Receivables
ÂĄ2.9B
CAGR 3-Years
26%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Receivables
ÂĄ6.8B
CAGR 3-Years
13%
CAGR 5-Years
41%
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Total Receivables
ÂĄ931.5m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Total Receivables
ÂĄ985.8m
CAGR 3-Years
177%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
42.6B CNY
Industry
Life Sciences Tools & Services

Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market. Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.

Intrinsic Value
69.85 CNY
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Total Receivables?
Total Receivables
4.3B CNY

Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Total Receivables amounts to 4.3B CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
33%

Over the last year, the Total Receivables growth was 10%. The average annual Total Receivables growth rates for Hangzhou Tigermed Consulting Co Ltd have been 31% over the past three years , 31% over the past five years , and 33% over the past ten years .

Back to Top